Home › Agent Hub › Agent Tools › Part D coverage by drug › Edarbi
Agent Tools
Edarbi is a brand of azilsartan. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 2,567 of 5,496 Medicare Part D and Medicare Advantage drug plans (46.7%) list Edarbi on their formulary, across 82 of 328 formularies. The most common placement is tier 4 (1,943 plans, 75.7% of those covering it). 0 of the covering plans require prior authorization (0%), 279 step therapy and 2,153 a quantity limit.
281 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $47, 25 of them $0; 2,286 charge coinsurance instead — median 25% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 3,142 of 5,631 plans covered it (55.8%); 2026: 2,567 of 5,496 (46.7%).
Of 4,368 plans offered in both years, 37 added it to the formulary and 278 dropped it.
Among plans covering it both years, 68 moved it to a higher tier and 0 to a lower one; 0 added prior authorization and 0 removed it.
Medicare Part D paid for 150,556 30-day fills of Edarbi in 2024 for about 16,499 enrollees, at an average total cost of $243.32 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Edarbi and the rest of a client's list on every plan in their county.
Estimate Edarbi costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.